Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. The Paris-based company is collaborating with Marengo Therapeutics on the development of two drugs that selectively activate T cells to fight cancer.
Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets of the startup are mutations of KRAS and p53, both of which have proven difficult to drug.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies' potential outside of the blood cancer space.
The companies said Thursday that they would develop T-cell receptor therapies for cancers. Immatics, based in Germany, has several TCRs already in the clinic.
Celgene will have opt-in rights to take responsibility for development, manufacturing and commercialization of T-cell receptor therapies that Immatics develops using its in-house technology.
The company's product is a T-cell receptor therapy, or TCR. While TCRs have been restricted by genotype, Pact says it has engineered its cells to overcome that restriction.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company, part of Gilead Sciences since 2017, had placed an early emphasis on ensuring manufacturing capacity could meet demand - a key consideration in cell and gene therapy.
One report forecasts $25 billion in global sales in six years, but cell therapies to date have been slow to catch on.